Lung Cancer, An Issue of Hematology/Oncology Clinics of North America

1st Edition, Volume 37-3 - May 11, 2023
Editors: Sarah B. Goldberg, Roy S. Herbst
Language: English
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 3 0 6 - 5
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 3 0 7 - 2

In this issue of Hematology/Oncology Clinics, guest editors Drs. Sarah B. Goldberg and Roy S. Herbst bring their considerable expertise to the topic of Lung Cancer. Top experts in… Read more

Lung Cancer, An Issue of Hematology/Oncology Clinics of North America

Purchase options

Info / Buy

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Request a sales quote

In this issue of Hematology/Oncology Clinics, guest editors Drs. Sarah B. Goldberg and Roy S. Herbst bring their considerable expertise to the topic of Lung Cancer. Top experts in the field cover key topics such as state-of-the-art pathologic and molecular testing; neoadjuvant vs. adjuvant therapy for early-stage NSCLC; new therapies on the horizon (immunotherapy, ADCs, etc.); supportive care and symptom management; smoking cessation; and more.

Cover image
Title page
Table of Contents
Copyright
Contributors
Forthcoming Issues
Preface
State of the Art of Pathologic and Molecular Testing
Key points
Introduction
Discussion
Summary
Clinics care points
Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer
Key points
Introduction
Liquid biopsy throughout the continuum of care in non-small cell lung cancer
Liquid biopsy in advanced-stage non-small cell lung cancer: establishing new standards of care at initial diagnosis and at progressive disease in oncogene-driven disease
Liquid biopsy in treatment response monitoring
Liquid biopsy in detection of minimal residual disease
Emerging role of liquid biopsy in screening and early detection
Summary
Clinics care points
Disclosure
Advances in Surgical Techniques for Lung Cancer
Key points
Background
Current operative techniques
Surgery in the setting of neoadjuvant therapy
Segmentectomy and sublobar resection for early-stage non–small cell lung cancer
Surgical management of ground-glass opacities
Navigational bronchoscopy
Summary
Disclosures
Funding
Author contributions
Nonsurgical Therapy for Early-Stage Lung Cancer
Key points
Introduction
What is stereotactic ablative radiotherapy?
Clinical history of stereotactic ablative radiotherapy
Clinical outcomes following stereotactic ablative radiotherapy
Technical aspects of stereotactic ablative radiotherapy
High-risk treatment scenarios
Role of systemic therapy
Image-guided thermal ablation techniques for early-stage non-small cell lung cancer
Ablation for early-stage non-small cell lung cancer
Summary
Clinics care points
Source of funding
Declaration of interest
Supplementary data
The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer
Key points
Introduction
Adjuvant systemic therapy in non-small cell lung cancer
Neoadjuvant systemic therapy in non-small cell lung cancer
Preoperative/perioperative versus postoperative systemic therapy
Additional considerations and future directions
Clinics care points
Locally Advanced Lung Cancer
Key points
Introduction
Sequential versus Concurrent Chemoradiation Therapy
Role of immunotherapy
Personalized, genotype-directed therapy
Summary
Clinics care points
Disclosure
First-Line Treatment of Driver-Negative Non–Small Cell Lung Cancer
Key points
Introduction
PD-L1 greater than or equal to fifty percent
PD-L1 less than fifty percent
Never-smokers
Duration of immunotherapy
Immunotherapy sensitivity, resistance, and exploratory biomarkers
Summary
Clinics care points
Disclosures
Targeted Therapy for Non–Small Cell Lung Cancer: First Line and Beyond
Key points
Introduction
Prevalence and identification of actionable oncogenic drivers
The fusion drivers: ALK, ROS1, RET, and NTRK
EGFR activating mutations
HER2 activating mutations
BRAF mutations
MET exon 14 skipping mutations
KRAS G12C mutations
Emerging oncogenic drivers as therapeutic targets
Immunotherapy in oncogene-driven lung cancer
Perioperative use of targeted therapy
Discussion
Clinics care points
Disclosure
What Is New in Small Cell Lung Cancer
Key points
Introduction
Summary
Clinics care points
Lung Cancer Supportive Care and Symptom Management
Key points
Introduction
Background
Mortality
Morbidity
Prognostic uncertainty
Oncologic emergencies
Symptoms
Palliative care
Lung cancer survivorship
Summary
Disclosure
New Therapies on the Horizon
Key points
Introduction
Strategies to overcome immune checkpoint inhibitors resistance
Antibody-drug conjugates
Discussion of future directions
Summary
Clinics care points
Disclosure of funding
Conflicts of interest

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Lung Cancer, An Issue of Hematology/Oncology Clinics of North America

Purchase options

Save 50% on book bundles

Institutional subscription on ScienceDirect

Sarah B. Goldberg

Roy S. Herbst